Advertisement
Skip to Content
Morningstar

Janus Henderson Global Life Sciences D JNGLX

Morningstar Analyst Rating
Quantitative rating as of | See Janus Henderson Investment Hub
  • NAV / 1-Day Return 67.16  /  0.70 %
  • Total Assets 4.7 Bil
  • Adj. Expense Ratio
    0.800%
  • Expense Ratio 0.800%
  • Distribution Fee Level Below Average
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Blend
  • Min. Initial Investment 2,500
  • Status Limited
  • TTM Yield 0.25%
  • Turnover 21%

USD | NAV as of Feb 07, 2023 | 1-Day Return as of Feb 07, 2023, 11:40 PM GMT+00:00

Morningstar’s Analysis JNGLX

Will JNGLX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Process Pillar

The Process Pillar is our assessment of how sensible, clearly defined, and repeatable JNGLX’s performance objective and investment process is for both security selection and portfolio construction.

People Pillar

The People Pillar is our evaluation of the JNGLX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

Parent Pillar

The Parent Pillar is our rating of JNGLX’s parent organization’s priorities and whether they’re in line with investors’ interests.

Summary

|

Janus Henderson Global Life Sciences D’s management team is just average, but a solid investment process still helps this strategy retain its Morningstar Quantitative Rating of Bronze. The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.

Unlock our full analysis with Morningstar Investor